Futibatinib

Futibatinib
Clinical data
Trade names	Lytgobi
Other names	TAS-120
AHFS/Drugs.com	Micromedex Detailed Consumer Information
License data	US DailyMed: Futibatinib;
Routes of; administration	By mouth
Drug class	Antineoplastic
ATC code	L01EN04 (WHO) ;
Legal status
Legal status	US: ℞-only[1][2][3][4];
Identifiers
	IUPAC name 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one;
CAS Number	1448169-71-8;
PubChem CID	71621331;
IUPHAR/BPS	9786;
DrugBank	DB15149;
ChemSpider	58877816;
UNII	4B93MGE4AL;
KEGG	D11725;
ChEMBL	ChEMBL3701238;
PDB ligand	TZ0 (PDBe, RCSB PDB);
Chemical and physical data
Formula	C22H22N6O3
Molar mass	418.457 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC(=CC(OC)=C1)C#CC1=NN([C@H]2CCN(C2)C(=O)C=C)C2=C1C(N)=NC=N2;
	InChI InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1; Key:KEIPNCCJPRMIAX-HNNXBMFYSA-N;

Futibatinib, sold under the brand name Lytgobi, is a medication used for the treatment of cholangiocarcinoma (bile duct cancer).[1][4] It is a kinase inhibitor.[1][5] It is taken by mouth.[1]

Futibatinib was approved for medical use in the United States in September 2022.[1][4][6][3]

Medical uses

Futibatinib is indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.[1][4][3]

Names

Futibatinib is the international nonproprietary name (INN).[7]

References

"Lytgobi (futibatinib) tablets, for oral use" (PDF). Archived (PDF) from the original on 4 October 2022. Retrieved 4 October 2022.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801Orig1s000lbledt.pdf
"FDA grants accelerated approval to futibatinib for cholangiocarcinoma". U.S. Food and Drug Administration. 30 September 2022. Retrieved 4 December 2022. This article incorporates text from this source, which is in the public domain.
"Drug Approval Package: Lytgobi". U.S. Food and Drug Administration (FDA). 8 November 2022. Retrieved 18 November 2022.
"Lytgobi (Futibatinib) FDA Approval History". Archived from the original on 4 October 2022. Retrieved 4 October 2022.
"FDA Approves Taiho's Lytgobi (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma" (Press release). Taiho Oncology. 30 September 2022. Archived from the original on 4 October 2022. Retrieved 4 October 2022 – via PR Newswire.
World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.

External links

"Futibatinib". Drug Information Portal. U.S. National Library of Medicine.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Lytgobi_FDA_label-1] "Lytgobi (futibatinib) tablets, for oral use" (PDF). Archived (PDF) from the original on 4 October 2022. Retrieved 4 October 2022.

[2] ttps://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801Orig1s000lbledt.pdf

[FDA_futibatinib-3] "FDA grants accelerated approval to futibatinib for cholangiocarcinoma". U.S. Food and Drug Administration. 30 September 2022. Retrieved 4 December 2022. This article incorporates text from this source, which is in the public domain.

[Lytgobi_Drug_Approval_Package-4] "Drug Approval Package: Lytgobi". U.S. Food and Drug Administration (FDA). 8 November 2022. Retrieved 18 November 2022.

[5] "Lytgobi (Futibatinib) FDA Approval History". Archived from the original on 4 October 2022. Retrieved 4 October 2022.

[6] "FDA Approves Taiho's Lytgobi (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma" (Press release). Taiho Oncology. 30 September 2022. Archived from the original on 4 October 2022. Retrieved 4 October 2022 – via PR Newswire.

[7] World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.